Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials

BACKGROUND: In the U.S.A., an Investigator's Global Assessment (IGA) score of ≤ 1 (clear or almost clear skin) has been the standard measure in regulatory outcomes for registration clinical trials in atopic dermatitis (AD), including those supporting the recent approval of dupilumab. OBJECTIVES...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Dermatol
Main Authors: Silverberg, J.I., Simpson, E.L., Ardeleanu, M., Thaçi, D., Barbarot, S., Bagel, J., Chen, Z., Eckert, L., Chao, J., Korotzer, A., Rizova, E., Rossi, A.B., Lu, Y., Graham, N.M.H., Hultsch, T., Pirozzi, G., Akinlade, B.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849829/
https://ncbi.nlm.nih.gov/pubmed/30791102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.17791
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados